Canadian cannabis stocks, including Tilray (TLRY), surged following reports that President Donald Trump could sign an executive order as soon as Monday reclassifying marijuana from a Schedule I drug like heroin to the less-restrictive Schedule III category, alongside steroids and codeine.
The potential reclassification would allow cannabis companies to deduct business expenses under IRS rules, improve access to banking services, and enable expanded medical research.
